BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27317395)

  • 1. Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.
    T'jollyn H; Snoeys J; Van Bocxlaer J; De Bock L; Annaert P; Van Peer A; Allegaert K; Mannens G; Vermeulen A; Boussery K
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):537-543. PubMed ID: 27317395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
    Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
    Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.
    T'jollyn H; Snoeys J; Colin P; Van Bocxlaer J; Annaert P; Cuyckens F; Vermeulen A; Van Peer A; Allegaert K; Mannens G; Boussery K
    Pharm Res; 2015 Jan; 32(1):260-74. PubMed ID: 25048637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.
    T'jollyn H; Snoeys J; Vermeulen A; Michelet R; Cuyckens F; Mannens G; Van Peer A; Annaert P; Allegaert K; Van Bocxlaer J; Boussery K
    AAPS J; 2015 Nov; 17(6):1376-87. PubMed ID: 26209290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) - a comparison with the chemical inhibition method.
    Umehara KI; Huth F; Gu H; Schiller H; Heimbach T; He H
    Drug Metab Pers Ther; 2017 Dec; 32(4):191-200. PubMed ID: 29176011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intersystem Extrapolation Factors Are Substrate-Dependent for CYP3A4: Impact on Cytochrome P450 Reaction Phenotyping.
    Dantonio AL; Doran AC; Obach RS
    Drug Metab Dispos; 2022 Mar; 50(3):249-257. PubMed ID: 34903590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs.
    Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
    Xenobiotica; 2004 Jul; 34(7):687-703. PubMed ID: 15672756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
    Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
    Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
    Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
    Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
    Han SY; Zhao HY; Zhou N; Zhou F; Li PP
    J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.
    Felmlee MA; Lon HK; Gonzalez FJ; Yu AM
    Drug Metab Dispos; 2008 Feb; 36(2):435-41. PubMed ID: 18048490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
    Yu A; Haining RL
    Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
    de Moraes NV; Lauretti GR; Coelho EB; Godoy AL; Neves DV; Lanchote VL
    Fundam Clin Pharmacol; 2016 Apr; 30(2):153-61. PubMed ID: 26947771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model.
    Ramsden D; Perloff ES; Whitcher-Johnstone A; Ho T; Patel R; Kozminski KD; Fullenwider CL; Zhang JG
    Drug Metab Dispos; 2022 Feb; 50(2):114-127. PubMed ID: 34789487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop.
    Shin YG; Le H; Khojasteh C; Hop CE
    Comb Chem High Throughput Screen; 2011 Nov; 14(9):811-23. PubMed ID: 21605066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans.
    Thörn HA; Lundahl A; Schrickx JA; Dickinson PA; Lennernäs H
    Eur J Pharm Sci; 2011 Jun; 43(3):89-98. PubMed ID: 21447389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH.
    Nielsen LM; Holm NB; Leth-Petersen S; Kristensen JL; Olsen L; Linnet K
    Drug Test Anal; 2017 May; 9(5):671-679. PubMed ID: 27400739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450.
    Seguin RP; Herron JM; Lopez VA; Dempsey JL; Xu L
    Chem Res Toxicol; 2019 Dec; 32(12):2466-2478. PubMed ID: 31730751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
    Jetter A; Fätkenheuer G; Frank D; Klaassen T; Seeringer A; Doroshyenko O; Kirchheiner J; Hein W; Schömig E; Fuhr U; Wyen C
    Antivir Ther; 2010; 15(7):975-83. PubMed ID: 21041912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unravelling the pharmacokinetics of aflatoxin B1:
    Lootens O; De Boevre M; Gasthuys E; Van Bocxlaer J; Vermeulen A; De Saeger S
    Front Microbiol; 2022; 13():988083. PubMed ID: 36110298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.